21 May 2009
Prediction of graft loss and death in patients with primary sclerosing cholangitis (PSC)
O Kornasiewicz, K Dudek, Z Lewandowski, R Stankiewicz, M KrawczykAnn Transplant 2009; 14(1): 44-44 :: ID: 880358
Abstract
Background: The prognosis of patients with PSC can be accurately determined using Mayo Clinic Score (MRS). This is a mathematical model which predicts patient's survival and helps to determine individual patient's prognosis. The purpose of the study was to determine the risk of graft loss and/or death of patients who were listed or transplanted for PSC.
Material/Methods: We analyzed data of 52 patients, who were placed on the
transplant list due to PSC between January 2000 and November 2008 and either had or hadn't liver transplantation. The primary end point (EP1) of the study was the death of patients of any cause. The secondary composed end point (EP2) was: recurrence of the PSC or appearance of CCC or death related to primary liver disease after OLTx. The time of observation was 60 months. According to obtained MRS the patients were divided into 3 equal groups: group A (MRS<0.56), group B (0.56≤MRS<1.56) and group C (MRS>1.56). Each patient had calculated MRS using Mayo formula. Analysis was performed using the LIFETEST and PHREG Procedure of SAS System.
Results: Risk of EP1 occurence was 2.0 per 1 point of MRS (p<0.0006). Risk of EP2 was 2.1 per 1 point of MRS (p< 0.001). In groups B and C compared with group A the risk of death were: 0.79(NS) and 6.59(p<0.08), respectively. Percentages of 5 years patients survival rate were 94%, 94% and 45% according to groups A, B and C, respectively.
Conclusions: The risk of death in patients with Mayo Risk Score above 1.56 is 6.59 fold higher compared to those with MRS below 0.56 (Group A). MRS greater than 1.56 significantly decreases 5 years survival of patients with primary sclerosing cholangitis.
Keywords: Liver Transplantation, clinical outcome
In Press
15 Mar 2024 : Review article
Approaches and Challenges in the Current Management of Cytomegalovirus in Transplant Recipients: Highlighti...Ann Transplant In Press; DOI: 10.12659/AOT.941185
18 Mar 2024 : Original article
Does Antibiotic Use Increase the Risk of Post-Transplantation Diabetes Mellitus? A Retrospective Study of R...Ann Transplant In Press; DOI: 10.12659/AOT.943282
20 Mar 2024 : Original article
Transplant Nephrectomy: A Comparative Study of Timing and Techniques in a Single InstitutionAnn Transplant In Press; DOI: 10.12659/AOT.942252
28 Mar 2024 : Original article
Association Between FEV₁ Decline Rate and Mortality in Long-Term Follow-Up of a 21-Patient Pilot Clinical T...Ann Transplant In Press; DOI: 10.12659/AOT.942823
Most Viewed Current Articles
05 Apr 2022 : Original article
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
12 Jan 2022 : Original article
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
22 Nov 2022 : Original article
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860